An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
Dr. Maryam Lustberg discusses the REVITALIZE trial testing CO2 laser therapy to treat vaginal dryness and GSM in breast ...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces further compelling evidence from a multicenter, ...
In this Q&A, Mwango Kashoki, MD, MPH, SVP and global head of regulatory strategy at Parexel, breaks down the FDA's plausible ...
A study failed to show significant cognitive benefits with exercise over 2 years, but the rewards are more likely to manifest ...
Statin come with heavy baggage. I decided to treat a knowledge gap using my own body in a blinded crossover ...
Morning Overview on MSN
New bowel cancer approach keeps disease at bay for 3 years
Every patient enrolled in a groundbreaking rectal cancer trial has remained disease-free for more than three years after ...
After Replimune’s advanced melanoma drug was rejected for a second time, CEO Sushil Patel slammed the FDA for failing to ...
Surfshark, a leading VPN provider, is revolutionizing the consumer VPN industry with the launch of its own VPN protocol, Dausos. While traditional VPNs consolidate all user traffic through a single ...
Warren Buffett's simple "market closure test" reveals why millions of stressed retail investors are doing investing wrong.
When IVUS did not outperform angiography for guiding percutaneous interventions in two trials, the results offered more questions than answers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results